Nuvation Bio NUVB Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Nuvation Bio (NUVB) reported debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss of $21K in Q4 2025.
- How has Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss changed year-over-year?
- Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss decreased by 95.1% year-over-year, from $431K to $21K.
- What is the long-term trend for Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Over 4 years (2021 to 2025), Nuvation Bio's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss has grown at a -66.7% compound annual growth rate (CAGR), from $1.71M to $21K.